Angiotensin II Acetate 50 µg/vial (Clinalfa basic)


A considerable number of publications on Clinalfa products used in clinical trials are available. The most important publications are listed below. For a comprehensive list please contact us.


All information is compiled to the best of our knowledge. We cannot be made liable for any possible errors or misprints.


Literature references citing the Clinalfa basic product


van Twist, D. J., Houben, A. J., de Haan, M. W., Mostard, G. J., Kroon, A. A. and de Leeuw, P. W.
Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion.
Hypertension 62, 789-793 (2013)



Boschmann, M., Adams, F., Schaller, K., Franke, G., Sharma, A. M., Klaus, S., Luft, F. C. and Jordan, J.
Hemodynamic and metabolic responses to interstitial angiotensin II in normal weight and obese men.
J. Hypertens. 24, 1165-1171 (2006)

Houben, A. J., Burgwinkel, J. P. and de Leeuw, P. W.
A novel approach to the study of human microcirculation: Reactivity to locally applied angiotensin II in the conjunctival microvascular bed.
J. Hypertens. 24, 2225-2230 (2006)

Luther, J. M., Gainer, J. V., Murphey, L. J., Yu, C., Vaughan, D. E., Morrow, J. D. and Brown, N. J.
Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
Hypertension 48, 1050-1057 (2006)

Morgan, D. R., Dixon, L. J., Hanratty, C. G., El-Sherbeeny, N., Hamilton, P. B., McGrath, L. T., Leahey, W. J., Johnston, G. D. and McVeigh, G. E.
Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure.
Am. J. Cardiol. 97, 547-551 (2006)

Schachinger, H., Klarhofer, M., Linder, L., Drewe, J. and Scheffler, K.
Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal.
Hypertension 47, 1062-1066 (2006)



Bleeker, M. W., Kooijman, M., Rongen, G. A., Hopman, M. T. and Smits, P.
Preserved contribution of nitric oxide to baseline vascular tone in deconditioned human skeletal muscle.
J. Physiol. 565, 685-694 (2005)

Hasler, C., Nussberger, J., Maillard, M., Forclaz, A., Brunner, H. R. and Burnier, M.
Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Clin. Pharmacol. Ther. 78, 501-507 (2005)

Kistler, P. M., Davidson, N. C., Sanders, P., Fynn, S. P., Stevenson, I. H., Spence, S. J., Vohra, J. K., Sparks, P. B. and Kalman, J. M.
Absence of acute effects of angiotensin II on atrial electrophysiology in humans.
J. Am. Coll. Cardiol. 45, 154-156 (2005)



Fleischmann, E. H., John, S., Delles, C., Schneider, M. P., Schmidt, B. M. and Schmieder, R. E.
The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.
Am. J. Hypertens. 17, 1120-1126 (2004)

Gossl, M., Mitchell, A., Lerman, A., Opazo Saez, A., Schafers, R. F., Erbel, R., Philipp, T. and Wenzel, R. R.
Endothelin-B-receptor-selective antagonist inhibits endothelin-1 induced potentiation on the vasoconstriction to noradrenaline and angiotensin II.
J. Hypertens. 22, 1909-1916 (2004)

Mitchell, A., Luckebergfeld, B., Buhrmann, S., Rushentsova, U., Nurnberger, J., Siffert, W., Schafers, R. F., Philipp, T. and Wenzel, R. R.
Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism.
Clin. Pharmacol. Ther. 76, 396-408 (2004)

Morgan, D. R., Dixon, L. J., Hanratty, C. G., Hughes, S. M., Leahey, W. J., Rooney, K. P., Johnston, G. D. and McVeigh, G. E.
Impaired endothelium-dependent and -independent vasodilation in elderly patients with chronic heart failure.
Eur. J. Heart Fail. 6, 901-908 (2004)

Sim, J. S., Dick, J. B. and Struthers, A. D.
Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients.
J. Renin. Angiotensin Aldosterone Syst. 5, 109-113 (2004)

Spaanderman, M. E., Ekhart, T. H., de Leeuw, P. W. and Peeters, L. L.
Angiotensin II sensitivity in nonpregnant formerly preeclamptic women and healthy parous controls.
J. Soc. Gynecol. Investig. 11, 416-422 (2004)



Boschmann, M., Jordan, J., Adams, F., Christensen, N. J., Tank, J., Franke, G., Stoffels, M., Sharma, A. M., Luft, F. C. and Klaus, S.
Tissue-specific response to interstitial angiotensin II in humans.
Hypertension 41, 37-41 (2003)

Helmy, A., Newby, D. E., Jalan, R., Johnston, N. R., Hayes, P. C. and Webb, D. J.
Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis.
J. Hepatol. 38, 44-50 (2003)

Lottermoser, K., Unger, T., Gohlke, P., Vetter, H. and Dusing, R.
Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
Am. J. Hypertens. 16, 445-452 (2003)

Millasseau, S. C., Kelly, R. P., Ritter, J. M. and Chowienczyk, P. J.
The vascular impact of aging and vasoactive drugs: comparison of two digital volume pulse measurements.
Am. J. Hypertens. 16, 467-472 (2003)

Miller, J. A., Curtis, J. R. and Sochett, E. B.
Relationship between diurnal blood pressure, renal hemodynamic function, and the renin-angiotensin system in type 1 diabetes.
Diabetes 52, 1806-1811 (2003)

Pleiner, J., Mittermayer, F., Schaller, G., Marsik, C., MacAllister, R. J. and Wolzt, M.
Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress.
J. Am. Coll. Cardiol. 42, 1656-1662 (2003)

Vittorio, T. J., Lang, C. C., Katz, S. D., Packer, M., Mancini, D. M. and Jorde, U. P.
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Circulation 107, 290-293 (2003)



de Haas, S. L., Wilkinson, I. B., Boyd, J. L. and Webb, D. J.
Local nitric oxide release does not affect tachyphylaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition.
Br. J. Clin. Pharmacol. 53, 193-195 (2002)

Farquharson, C. A. and Struthers, A. D.
Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.
Clin. Sci. (Lond) 103, 425-431 (2002)

Jorde, U. P., Vittorio, T., Katz, S. D., Colombo, P. C., Latif, F. and Le Jemtel, T. H.
Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
Circulation 106, 1055-1057 (2002)

Rehman, A., Rahman, A. R. and Rasool, A. H.
Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
J. Hum. Hypertens. 16, 261-266 (2002)

Schou, M., Gabrielsen, A., Bruun, N. E., Skott, P., Pump, B., Dige-Petersen, H., Frandsen, E., Bie, P., Warberg, J., Christensen, N. J. and Norsk, P.
Angiotensin II attenuates the natriuresis of water immersion in humans.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R187-196 (2002)

van der Kleij, F. G., de Jong, P. E., Henning, R. H., de Zeeuw, D. and Navis, G.
Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake.
J. Am. Soc. Nephrol. 13, 1025-1033 (2002)

Wenzel, R. R., Siffert, W., Bruck, H., Philipp, T. and Schafers, R. F.
Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation.
Pharmacogenetics 12, 489-495 (2002)

Wilkinson, I. B., Affolter, J. T., de Haas, S. L., Pellegrini, M. P., Boyd, J., Winter, M. J., Balment, R. J. and Webb, D. J.
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.
Cardiovasc. Res. 53, 341-347 (2002)



Berlowitz, M. S., Latif, F., Hankins, S. R., Ennezat, P. V., Moskowitz, R., Tandon, S., Colombo, P. C. and Le Jemtel, T. H.
Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers.
J. Cardiovasc. Pharmacol. 37, 692-696 (2001)

Hilgers, K. F., Delles, C., Veelken, R. and Schmieder, R. E.
Angiotensinogen gene core promoter variants and non-modulating hypertension.
Hypertension 38, 1250-1254 (2001)

Kelly, R. P., Millasseau, S. C., Ritter, J. M. and Chowienczyk, P. J.
Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men.
Hypertension 37, 1429-1433 (2001)

Petrie, M. C., McDonald, J. E., Hillier, C., Morton, J. J. and McMurray, J. J.
Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans.
Br. J. Clin. Pharmacol. 52, 165-168 (2001)

Rehman, A., Rahman, A. R., Rasool, A. H. and Naing, N. N.
The effects of angiotensin II on pulse wave velocity in healthy humans.
Int. J. Clin. Pharmacol. Ther. 39, 423-430 (2001)

Troughton, R. W., Frampton, C. M., Lewis, L. K., Yandle, T. G., Richards, A. M. and Nicholls, M. G.
Differing thresholds for modulatory effects of adrenomedullin infusion on haemodynamic and hormone responses to angiotensin II and adrenocorticotrophic hormone in healthy volunteers.
Clin. Sci. (Lond) 101, 103-109 (2001)

Wenzel, R. R., Ruthemann, J., Bruck, H., Schafers, R. F., Michel, M. C. and Philipp, T.
Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man.
Br. J. Clin. Pharmacol. 52, 151-157 (2001)

Wilkinson, I. B., MacCallum, H., Hupperetz, P. C., van Thoor, C. J., Cockcroft, J. R. and Webb, D. J.
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man.
J. Physiol. 530, 541-550 (2001)



Farquharson, C. A. and Struthers, A. D.
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Circulation 101, 594-597 (2000)

Freudenthaler, S. M., Lucht, I., Schenk, T., Brink, M. and Gleiter, C. H.
Dose-dependent effect of angiotensin II on human erythropoietin production.
Pflugers Arch. 439, 838-844 (2000)

Helmy, A., Jalan, R., Newby, D. E., Hayes, P. C. and Webb, D. J.
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.
Gastroenterology 118, 565-572 (2000)

Kraiczi, H., Hedner, J., Peker, Y. and Carlson, J.
Increased vasoconstrictor sensitivity in obstructive sleep apnea.
J. Appl. Physiol. 89, 493-498 (2000)

Labinjoh, C., Newby, D. E., Dawson, P., Johnston, N. R., Ludlam, C. A., Boon, N. A. and Webb, D. J.
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
Cardiovasc. Res. 47, 707-714 (2000)

Larsson, P. T., Schwieler, J. H. and Wallen, N. H.
Platelet activation during angiotensin II infusion in healthy volunteers.
Blood Coagul. Fibrinolysis 11, 61-69 (2000)

Lee, A. F., McFarlane, L. C. and Struthers, A. D.
Ovarian hormones in man: their effects on resting vascular tone, angiotensin converting enzyme activity and angiotensin II-induced vasoconstriction.
Br. J. Clin. Pharmacol. 50, 73-76 (2000)

Maillard, M. P., Rossat, J., Nussberger, J., Ramis, J., Pontes, C., Burnier, M. and Brunner, H. R.
Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.
J. Cardiovasc. Pharmacol. 35, 383-389 (2000)

Petrie, M. C., Hillier, C., Morton, J. J. and McMurray, J. J.
Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans.
J. Hypertens. 18, 61-64 (2000)

Saris, J. J., van Dijk, M. A., Kroon, I., Schalekamp, M. A. and Danser, A. H.
Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm.
Hypertension 35, 764-768 (2000)

Ueda, S., Masumori-Maemoto, S., Ashino, K., Nagahara, T., Gotoh, E., Umemura, S. and Ishii, M.
Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man.
Hypertension 35, 998-1001 (2000)



Anumba, D. O., Robson, S. C., Boys, R. J. and Ford, G. A.
Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy.
Am. J. Physiol. 277, H848-854 (1999)



Newby, D. E., Goodfield, N. E., Flapan, A. D., Boon, N. A., Fox, K. A. and Webb, D. J.
Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.
Heart 80, 134-140 (1998)

Newby, D. E., Jalan, R., Masumori, S., Hayes, P. C., Boon, N. A. and Webb, D. J.
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems.
Cardiovasc. Res. 38, 221-228 (1998)